Kazia Therapeutics Limited fa'asalalau fa'amatalaga fou fa'apitoa e fa'aalia ai le gaioiga o le paxalisib i ituaiga e lua o le kanesa o le fai'ai o tamaiti ma le maualuga tele o mana'oga fa'afoma'i.
O faʻamaumauga nei o le autu lea o faʻamatalaga e tolu na tuʻuina atu i le Fonotaga Faaletausaga a le American Association for Cancer Research (AACR), na faia i New Orleans, LA, mai Aperila 8 - 13, 2022.
E lua fa'amatalaga a saienitisi o lo'o galulue i le falesu'esu'e a le Polofesa Lagolago Jeffrey Rubens i le Iunivesite o Johns Hopkins i Baltimore, MD, o lo'o fa'amatalaina ai le fa'aogaina o le paxalisib e fai ma togafiti i tua i le kanesa o le fai'ai a'o laiti e ta'ua o atypical teratoid/rhabdoid tumors (AT/RT). O le taimi muamua lea ua tu'uina atu ai fa'amaumauga e su'esu'e ai le paxalisib i lenei ituaiga o kanesa o le fai'ai, ma ua tatalaina ai se fa'ailoga fou taua mo le vaila'au.
O le vaega lona tolu, mai se vaega eseese o saienitisi i le Iunivesite o Johns Hopkins, taʻitaʻia e le Polofesa Lagolago Eric Raabe ma Dr Katherine Barnett, na faʻaalia ai le faʻamaoniga malosi o le fesoʻotaʻiga i le va o le paxalisib ma le isi vasega o togafitiga o le kanesa i se faʻataʻitaʻiga o le diffuse intrinsic pontine glioma (DIPG) . Paxalisib ua faʻaalia muamua faʻamaoniga o gaioiga i lenei faʻamaʻi, e le gata i le monotherapy ma faʻatasi ma le tele o ituaiga o togafitiga o le kanesa, ma o faʻamaumauga fou e faʻamaonia atili ai lona gafatia i lenei faʻamaʻi faigata tele.
Manatu autu
• AT/RT ose kanesa fai'ai e seasea ona a'afia ai pepe ma tamaiti laiti. E leai ni vaila'au fa'amaonia e le FDA mo AT/RT ma e fa'atapula'a lava filifiliga o lo'o iai. E itiiti ifo ma le tasi i le lima gasegase e ola i le silia ma le lua tausaga mai le suʻesuʻeina.
• Fa'amaumauga mai le falesu'esu'e a Polofesa Rubens o lo'o fa'aalia ai o le ala PI3K e masani ona fa'agaoioia ile AT/RT, ma o le togafitiga fa'atasi ma le paxalisib o lo'o galue i fa'ata'ita'iga muamua o le ma'i. E le gata i lea, faʻatasi ma le RG2822, o le HDAC inhibitor, poʻo le TAK580, o le MAPK inhibitor, e foliga mai e faʻalauteleina le ola pe a faʻatusatusa i togafitiga monotherapy.
• O le DIPG ose kanesa fai'ai e seasea maua e masani ona vaaia i tamaiti laiti ma tupulaga talavou. E leai ni vaila'au fa'amaonia e le FDA, ma o le averesi o le umi o le ola mai fa'ama'i e masani lava e tusa ma le sefulu masina.
• Fa'amatalaga muamua mai le tele o 'au o tagata su'esu'e, ae maise mai le 'au a Polofesa Matt Dun i le Hunter Medical Research Institute, ua fa'aalia ai o le paxalisib e malosi tele i le DIPG ma tu'ufa'atasia ma le tele o vaila'au o le kanesa.
• Faʻamatalaga mai Drs Raabe ma Barnett ma paʻaga e faʻamaonia ai se tuʻufaʻatasiga togafitiga faʻaopoopo, faʻatasi ai ma le HDAC inhibitor RG2833, o loʻo faʻaalia ai faʻamaoniga o le malosi faʻatasi i se faʻataʻitaʻiga muamua o le DIPG.
Kazia CEO, Dr James Garner, faʻaopoopo, "O se faʻamatalaga faʻamaonia tele, ma matou te faʻafetai i le 'au i Johns Hopkins mo lenei suʻesuʻega taua ma faʻamalosia. Paxalisib ua leva ona avea ma autu o se faʻataʻitaʻiga faʻapitoa II faʻataʻitaʻiga ile DIPG ma faʻasalalau midline gliomas (NCT05009992) ma o nei faʻamatalaga fou e taʻu mai ai le tele o talosaga mo le vailaʻau i gasegase o le faiʻai o tamaiti. Matou te tulimatai atu e galulue ma le Johns Hopkins team, ma isi paaga ma faufautua, e suʻesuʻe atili nei avanoa.
OA MEA E AVEA MAI LENEI TUSI:
- Two abstracts by scientists working in the laboratory of Assistant Professor Jeffrey Rubens at Johns Hopkins University in Baltimore, MD, describe the use of paxalisib as a backbone therapy in a childhood brain cancer known as atypical teratoid / rhabdoid tumours (AT/RT).
- The third abstract, from a different team of scientists at Johns Hopkins University, led by Associate Professor Eric Raabe and Dr Katherine Barnett, showed evidence of strong synergy between paxalisib and another class of cancer therapies in a model of diffuse intrinsic pontine glioma (DIPG).
- Paxalisib is already the subject of an ongoing phase II clinical trial in DIPG and diffuse midline gliomas (NCT05009992) and this new data suggests potential wider applications for the drug in childhood brain cancers.
